Clostridium butyricum cDNA and Antigen

Clostridium butyricum is a Gram-positive, spore-forming bacterium commonly found in the human gut. Recent studies have shown that this bacterium has a wide range of health benefits, including improved gut health, enhanced immune function, and protection against certain diseases. In this article, we will focus on the different antigens produced by Clostridium butyricum, specifically the 67 kDa myosin-cross-reactive antigen, epidermal surface antigen, surface protective antigen SpaA, and SpaC, and their role in maintaining optimal health.

67 kDa Myosin-Cross-Reactive Antigen: The 67 kDa myosin-cross-reactive antigen (MCRA) is a protein produced by Clostridium butyricum that has been shown to have a range of health benefits. It is involved in the production of short-chain fatty acids (SCFAs) in the gut, which are essential for maintaining a healthy gut microbiota. SCFAs also have anti-inflammatory properties, which can help protect against inflammatory bowel disease (IBD) and other gut-related conditions.

Epidermal Surface Antigen: The epidermal surface antigen (ESA) is another protein produced by Clostridium butyricum that has been shown to have health benefits. It is involved in the regulation of the immune system, specifically by enhancing the activity of regulatory T-cells. These cells play a critical role in maintaining immune tolerance, which is essential for preventing autoimmune diseases and allergies.

Surface Protective Antigen SpaA and SpaC: The surface protective antigen SpaA and SpaC are two other proteins produced by Clostridium butyricum that have been shown to have protective effects on the gut lining. They work by enhancing the production of mucus, which serves as a barrier against harmful pathogens and toxins. This helps prevent gut-related conditions such as leaky gut syndrome and IBD.

Clostridium butyricum and its antigens have shown great promise in maintaining optimal health, particularly in the gut. The 67 kDa myosin-cross-reactive antigen, epidermal surface antigen, surface protective antigen SpaA, and SpaC have all been shown to have a range of health benefits, from improving gut health to enhancing immune function and protecting against certain diseases. As research into these antigens continues, we can expect to learn more about their role in maintaining optimal health and preventing disease.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Clostridium butyricum cDNA and recombinant antigens are essential tools for studying the molecular biology of this important bacterium. They provide a reliable source of genetic material for use in research, diagnosis and development of therapeutic strategies for diseases caused by C. butyricum. These cDNA and recombinant antigens are also useful for vaccine development, as they can be used to generate antibodies that can be used to detect and protect against C. butyricum infections.